Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib in Recalcitrant Frontal Fibrosing Alopecia
NCT06202560Completed
- Sponsor
- St John's Institute of Dermatology
- Start
- Nov 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tofacitinib oral solution in frontal fibrosing alopecia (FFA), sponsored by St John's Institute of Dermatology. Primary endpoints: Frontal Fibrosing Alopecia Severity Index at 16 weeks, Frontal Fibrosing Alopecia Severity Score at 16 weeks and 1 more. Started Nov 2023; status: completed.
02
Drugs
tofacitinib oral solution
03
Conditions
frontal fibrosing alopecia (FFA)
Beyond the preview
Go deeper on NCT06202560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06202560.